These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry. Hoedemaker NPG; Damman P; Ottervanger JP; Dambrink JHE; Gosselink ATM; Kedhi E; Kolkman E; de Winter RJ; van 't Hof AWJ Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):127-138. PubMed ID: 30084902 [TBL] [Abstract][Full Text] [Related]
23. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC; Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498 [TBL] [Abstract][Full Text] [Related]
24. Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction. Verschuren JJ; Boden H; Wessels JA; van der Hoeven BL; Trompet S; Heijmans BT; Putter H; Guchelaar HJ; Schalij MJ; Jukema JW Int J Cardiol; 2013 Sep; 167(6):2882-8. PubMed ID: 22940005 [TBL] [Abstract][Full Text] [Related]
25. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Stockl KM; Le L; Zakharyan A; Harada AS; Solow BK; Addiego JE; Ramsey S Arch Intern Med; 2010 Apr; 170(8):704-10. PubMed ID: 20421557 [TBL] [Abstract][Full Text] [Related]
26. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Evanchan J; Donnally MR; Binkley P; Mazzaferri E Clin Cardiol; 2010 Mar; 33(3):168-71. PubMed ID: 20235209 [TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction. Depta JP; Lenzini PA; Lanfear DE; Wang TY; Spertus JA; Bach RG; Cresci S Pharmacogenomics J; 2015 Feb; 15(1):20-5. PubMed ID: 25001880 [TBL] [Abstract][Full Text] [Related]
28. Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010. Puymirat E; Schiele F; Ennezat PV; Coste P; Collet JP; Bonnefoy-Cudraz E; Roul G; Richard P; Simon T; Danchin N Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):211-9. PubMed ID: 25075006 [TBL] [Abstract][Full Text] [Related]
29. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Jeong YH; Tantry US; Kim IS; Koh JS; Kwon TJ; Park Y; Hwang SJ; Bliden KP; Kwak CH; Hwang JY; Gurbel PA Circ Cardiovasc Interv; 2011 Dec; 4(6):585-94. PubMed ID: 22045970 [TBL] [Abstract][Full Text] [Related]
30. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction. Fontes-Carvalho R; Albuquerque A; Araújo C; Pimentel-Nunes P; Ribeiro VG Eur J Gastroenterol Hepatol; 2011 May; 23(5):396-404. PubMed ID: 21464720 [TBL] [Abstract][Full Text] [Related]
31. Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry. Orban M; Mayer K; Morath T; Bernlochner I; Hadamitzky M; Braun S; Schulz S; Hoppmann P; Hausleiter J; Tiroch K; Mehilli J; Schunkert H; Massberg S; Laugwitz KL; Sibbing D; Kastrati A Thromb Haemost; 2014 Dec; 112(6):1190-7. PubMed ID: 25183544 [TBL] [Abstract][Full Text] [Related]
32. Comparison of efficacy and safety of a standard versus a loading dose of clopidogrel for acute myocardial infarction in patients ≥ 75 years of age (from the FAST-MI registry). Puymirat E; Aïssaoui N; Coste P; Dentan G; Bataille V; Drouet E; Mulak G; Carrié D; Blanchard D; Simon T; Danchin N Am J Cardiol; 2011 Sep; 108(6):755-9. PubMed ID: 21726837 [TBL] [Abstract][Full Text] [Related]
33. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4). Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ; Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312 [TBL] [Abstract][Full Text] [Related]
34. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. Kim IS; Jeong YH; Park Y; Park KS; Yun SE; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S JACC Cardiovasc Interv; 2011 Apr; 4(4):381-91. PubMed ID: 21511217 [TBL] [Abstract][Full Text] [Related]
35. Cytochrome P450 2C19 polymorphism and clopidogrel after MI. Miao J; Liu R; Li Z Lancet; 2009 Apr; 373(9670):1171-2; author reply 1172-3. PubMed ID: 19345824 [No Abstract] [Full Text] [Related]
36. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. Bergmeijer TO; Janssen PW; Schipper JC; Qaderdan K; Ishak M; Ruitenbeek RS; Asselbergs FW; van 't Hof AW; Dewilde WJ; Spanó F; Herrman JP; Kelder JC; Postma MJ; de Boer A; Deneer VH; ten Berg JM Am Heart J; 2014 Jul; 168(1):16-22.e1. PubMed ID: 24952855 [TBL] [Abstract][Full Text] [Related]
37. Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome. Hsiao FY; Mullins CD; Wen YW; Huang WF; Chen PF; Tsai YW Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1043-9. PubMed ID: 21823195 [TBL] [Abstract][Full Text] [Related]
38. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. Jang JS; Cho KI; Jin HY; Seo JS; Yang TH; Kim DK; Kim DS; Seol SH; Kim DI; Kim BH; Park YH; Je HG; Jeong YH; Lee SW Am J Cardiol; 2012 Aug; 110(4):502-8. PubMed ID: 22591668 [TBL] [Abstract][Full Text] [Related]
39. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. Grosdidier C; Quilici J; Loosveld M; Camoin L; Moro PJ; Saut N; Gaborit B; Pankert M; Cohen W; Lambert M; Beguin S; Morange PE; Bonnet JL; Alessi MC; Cuisset T Am J Cardiol; 2013 Apr; 111(7):985-90. PubMed ID: 23340030 [TBL] [Abstract][Full Text] [Related]